{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"KalVista Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"KALV"},"Address":{"label":"Address","value":"55 CAMBRIDGE PARKWAY,SUITE 901 EAST, CAMBRIDGE, Massachusetts, 02142, United States"},"Phone":{"label":"Phone","value":"+1 857 999-0075"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.kalvista.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Benjamin L. Palleiko","title":"Chief Executive Officer & Director"},{"name":"Edward P. Feener","title":"Chief Scientific Officer"},{"name":"Paul K. Audhya","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}